Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwin Dreesen

Showing results (51-60 of 105) with videos related to

Pageof 11
Sort By:
Therapeutic Drug Monitoring|December 3, 2024
Dose Optimization of Amikacin in the Emergency Department: A Population Pharmacokinetics Simulation StudyNada Dia, Sabrina De Winter, Matthias Gijsen, et al.
Clinical Pharmacokinetics|September 20, 2024
Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software ToolsYannick Hoffert, Nada Dia, Tim Vanuytsel, et al.
Inflammatory Bowel Diseases|August 3, 2019
A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative ColitisErwin Dreesen, Wannee Kantasiripitak, Iris Detrez, et al.
British Journal of Clinical Pharmacology|February 19, 2021
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseasesWannee Kantasiripitak, Bram Verstockt, Dahham Alsoud, et al.
Journal of Crohn'S & Colitis|January 20, 2023
A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel DiseasesWannee Kantasiripitak, Sebastian G Wicha, Debby Thomas, et al.
The American Journal of Gastroenterology|August 3, 2016
A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel DiseaseThomas Billiet, Erwin Dreesen, Isabelle Cleynen, et al.
Clinical and Experimental Dermatology|March 4, 2022
Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasisRani Soenen, Zhigang Wang, Lynda Grine, et al.
The Journal of Pediatrics|September 5, 2021
Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination TherapyKaren van Hoeve, Nasim Sadat Seyed Tabib, Erwin Dreesen, et al.
Therapeutic Drug Monitoring|February 9, 2021
A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short CommunicationOmar Elkayal, Isabel Spriet, Anne Uyttebroeck, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 5, 2021
Bosentan Alters Endo- and Exogenous Bile Salt Disposition in Sandwich-Cultured Human HepatocytesMarlies Oorts, Pieter Van Brantegem, Neel Deferm, et al.
Pageof 11

Showing results (51-60 of 105) with videos related to

Sort By:
Pageof 11
Therapeutic Drug Monitoring|December 3, 2024
Dose Optimization of Amikacin in the Emergency Department: A Population Pharmacokinetics Simulation StudyNada Dia, Sabrina De Winter, Matthias Gijsen, et al.
Clinical Pharmacokinetics|September 20, 2024
Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software ToolsYannick Hoffert, Nada Dia, Tim Vanuytsel, et al.
Inflammatory Bowel Diseases|August 3, 2019
A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative ColitisErwin Dreesen, Wannee Kantasiripitak, Iris Detrez, et al.
British Journal of Clinical Pharmacology|February 19, 2021
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseasesWannee Kantasiripitak, Bram Verstockt, Dahham Alsoud, et al.
Journal of Crohn'S & Colitis|January 20, 2023
A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel DiseasesWannee Kantasiripitak, Sebastian G Wicha, Debby Thomas, et al.
The American Journal of Gastroenterology|August 3, 2016
A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel DiseaseThomas Billiet, Erwin Dreesen, Isabelle Cleynen, et al.
Clinical and Experimental Dermatology|March 4, 2022
Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasisRani Soenen, Zhigang Wang, Lynda Grine, et al.
The Journal of Pediatrics|September 5, 2021
Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination TherapyKaren van Hoeve, Nasim Sadat Seyed Tabib, Erwin Dreesen, et al.
Therapeutic Drug Monitoring|February 9, 2021
A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short CommunicationOmar Elkayal, Isabel Spriet, Anne Uyttebroeck, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 5, 2021
Bosentan Alters Endo- and Exogenous Bile Salt Disposition in Sandwich-Cultured Human HepatocytesMarlies Oorts, Pieter Van Brantegem, Neel Deferm, et al.
Pageof 11